Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.77 |
| ▸ | BRAF | P15056 | 1/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.65 |
| ▸ | YES1 | P07947 | 5/20 | 0.65 |
| ▸ | KDR | P35968 | 3/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | LCK | P06239 | 2/20 | 0.65 |
| ▸ | LYN | P07948 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | RAF1 | P04049 | 1/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.65 |
| ▸ | CSK | P41240 | 1/20 | 0.65 |
| ▸ | BLK | P51451 | 1/20 | 0.65 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501154 | 0.95 | SRC (0.69) | SRCBRAFPDGFRBYES1KDR | |
| SCHEMBL4276831 | 0.87 | SRC (1.00) | SRCPDGFRBYES1KDREPHB4 | |
| SCHEMBL226165 | 0.83 | SRC (0.55) | SRCBRAFPDGFRBYES1KDR | |
| SCHEMBL226164 | 0.83 | SRC (0.55) | SRCBRAFPDGFRBYES1KDR | |
| SCHEMBL2582023 | 0.81 | SRC (0.53) | SRCBRAFPDGFRBYES1KDR | |
| SCHEMBL29370842 | 0.81 | BRAF (0.68) | SRCBRAFYES1KDREPHB4 | |
| SCHEMBL229860 | 0.80 | BRAF (0.68) | SRCBRAFPDGFRBYES1KDR | |
| SCHEMBL231133 | 0.80 | SRC (0.51) | SRCBRAFPDGFRBYES1KDR | |
| SCHEMBL226245 | 0.80 | SRC (0.67) | SRCBRAFPDGFRBYES1KDR | |
| SCHEMBL4269573 | 0.79 | SRC (1.00) | SRCPDGFRBYES1KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | SRC 1325/4885BRAF 50/4885PDGFRB 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.